Mylan Entities Trimmed From Bausch Trulence Infringement Suit

Various Mylan entities won release from a patent infringement suit related to the drugmaker’s intention to sell a generic drug to treat constipation and irritable bowel syndrome because they didn’t take any steps toward marketing it, a federal court in New Jersey said.

Brand-name drugmakers Bausch Health Ireland Ltd. and Salix Pharmaceuticals Inc. can sue only Mylan Pharmaceuticals Inc. because it’s the only entity that’s seeking U.S. Food and Drug Administration approval to sell a generic version of a patented drug, the U.S. District Court for the District of New Jersey said.

The court also found that New Jersey wasn’t ...